Iopidine (Apraclonidine)

Apraclonidine acts as a selective alpha‑2 adrenergic receptor agonist in the eye. Stimulation of these receptors reduces the production of aqueous humor and modestly increases uveoscleral outflow, leading to a net decrease in intra‑ocular pressure.

The dosing regimen for Iopidine is determined by the prescribing ophthalmologist based on the patient’s condition, response, and tolerance. Typical practice involves one or two drops per eye, but the exact frequency and duration must be individualized by the healthcare professional.

Safety data for apraclonidine in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and use is recommended only if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a specialist is advised.

To order Iopidine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative class is beta‑blocker eye drops such as timolol. While beta‑blockers primarily reduce aqueous humor production, apraclonidine also modestly enhances uveoscleral outflow. Apraclonidine may be preferred when beta‑blockers are contraindicated or as an adjunct to achieve additional pressure reduction.

Iopidine should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from direct sunlight and moisture, and discard any solution that appears discolored or contains particles.

Iopidine is applied as an ophthalmic solution. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s) using a sterile technique. Patients should avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

Serious adverse events include severe allergic reactions (e.g., angio‑edema, anaphylaxis), acute angle‑closure glaucoma, significant systemic hypotension, and rare skin disorders such as Stevens‑Johnson syndrome. Any sudden vision change, eye pain, or systemic symptoms should prompt immediate medical evaluation.

Iopidine is contraindicated in individuals with known hypersensitivity to apraclonidine or any component of the formulation. Patients with narrow‑angle glaucoma should use it only under close supervision, and those taking MAO inhibitors should avoid it due to the risk of hypertensive crisis.